Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, April 19, 2025

Neurostimulant Use for Rehabilitation and Recovery After Stroke: A Narrative Literature Review

 I see nothing here that even remotely states what should be done to get recovered! You got published but DID NOTHING for getting survivors recovered!

Neurostimulant Use for Rehabilitation and Recovery After Stroke: A Narrative Literature Review

Helene Chesnais, BA https://orcid.org/0000-0002-3936-726X, Kelly L. Sloane, MD https://orcid.org/0000-0001-9680-9565, Jens Witsch, MD https://orcid.org/0000-0001-8924-851X, Christopher Favilla, MD https://orcid.org/0000-0003-0871-9549, Scott E. Kasner, MD https://orcid.org/0000-0003-0418-6917, and Aaron Rothstein, MD https://orcid.org/0000-0002-8480-8220 aaron.rothstein@pennmedicine.upenn.eduAuthor Info & Affiliations
Stroke
New online
https://doi.org/10.1161/STROKEAHA.124.048677

  • Abstract

    BACKGROUND:

    Stroke often results in significant impairments across various domains, including movement, language, cognition, and mood. Neurostimulants have been proposed as potential therapeutic interventions to enhance recovery in these areas.

    METHODS:

    This narrative literature review examines clinical trials investigating the efficacy of neurostimulants in poststroke recovery. It evaluates outcomes related to aphasia, motor deficits, cognition, fatigue, and depression.

    RESULTS:

    The qualitative analysis included 34 trials testing the following neurostimulants: methylphenidate (n=6), amphetamines (n=8), memantine (n=2), modafinil (n=2), levodopa (n=14), amantadine (n=1), bromocriptine (n=3), and ropinirole (n=1). Of the 34 studies, 31 were randomized, placebo-controlled (double-blind, n=27; single-blind, n=2; unblinded n=2), 2 were randomized and not placebo-controlled, and 1 was not randomized. Study design was either multiarm (n=23), crossover (n=10), or used subjects as their own control (n=1). Mean sample size was 49.4 (5–593).

    CONCLUSIONS:

    Current evidence suggests that memantine may be effective for aphasia, although few phase III trials exist, whereas bromocriptine and amphetamines lack sufficient evidence for long-term recovery of aphasia. Levodopa may improve motor aphasias but has not shown long-term benefits for motor recovery. Similarly, ropinirole has not been shown to improve poststroke motor outcomes. Methylphenidate has limited efficacy for cognitive improvement but may enhance poststroke functionality and mood. Modafinil may help with poststroke fatigue. In conclusion, there are promising results of positive effects of neurostimulants with few side effects, though studies are limited by heterogeneous designs and small sample sizes. Neurostimulant efficacy must be assessed in conjunction with specific rehabilitation modalities as part of larger, well-designed studies to best understand their effects on impairment.

    Graphical Abstract




    Get full access to this article

    Posted by at
    Labels: , , , , , , , ,

    No comments:

    Post a Comment

    Subscribe to: Post Comments (Atom)